Loading...
Market
Will Tecentriq Hybreza become the leading treatment for non-small cell lung cancer by market share in the US by mid-2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Market share reports from reputable healthcare analytics firms
Story
FDA Approves Genentech’s Tecentriq Hybreza, First Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy $RHHBY
Sep 12, 2024, 09:30 PM
The FDA has approved Genentech's Tecentriq Hybreza, making it the first subcutaneous anti-PD-(L)1 cancer immunotherapy available in the U.S. This approval marks a significant step in cancer treatment, providing a more accessible option for patients with non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, melanoma, and alveolar soft part sarcoma. Halozyme's ENHANZE technology played a crucial role in the development of this subcutaneous formulation. The stocks for Genentech ($RHHBY) and Halozyme ($HALO) are likely to be impacted by this approval.
View original story
Similar markets
Optune Lua with PD-1/PD-L1 inhibitors • 25%
Sunvozertinib • 25%
Durvalumab with chemotherapy • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Summit Therapeutics' ivonescimab • 25%
Merck's Keytruda • 25%
Roche's Tecentriq • 25%
Other • 25%
Novocure • 25%
AstraZeneca • 25%
Chinese Biotech Firms • 25%
Other • 25%
Ivonescimab > Keytruda • 25%
Ivonescimab = Keytruda • 25%
Ivonescimab < Keytruda • 25%
Neither has significant market share • 25%
Less than 20% • 25%
20%-40% • 25%
40%-60% • 25%
More than 60% • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Below 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
Above 60% • 25%
Yes • 50%
No • 50%
Less than 10% • 25%
10% to 19% • 25%
20% to 29% • 25%
30% or more • 25%